BETA BIONICS INC (BBNX)
Health Care · medical devices / diabetes care · NASDAQ
Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes.
What BETA BIONICS INC does
Beta Bionics is a medical technology company focused on the development and commercialization of automated insulin delivery systems for the management of diabetes. The company's primary technology is designed to simplify insulin delivery through automated control, with the goal of improving glycemic outcomes for individuals with diabetes.
Themes: diabetes management, automated insulin delivery, medical technology
Fundamentals
- Price$17.74 as of 2026-10-20 close
- Market cap$798M as of 2026-07-27 (share count; price 2026-10-20)
- 1-year return-12.4% 2025-10-20 close $20.24 → 2026-10-20 close $17.74
- P/En/a negative earnings
- Net margin-73.0% FY2025, SEC XBRL
- Gross margin+55.4% FY2025, SEC XBRL
- ROE-25.5% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+53.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+189.1% SEC XBRL
- Beta1.68 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How BBNX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $32M | $19M | -$26M | -$23M | -$0.53 | -$15M† | $1M† |
| Q1 FY2026 2026-03-31 | $28M | $16M | -$24M | -$22M | -$0.49 | -$24M | $1M |
| Q4 FY2025 2025-12-31 | $32M† | $19M† | -$16M† | -$13M† | -$0.29† | -$9M† | $2M† |
| Q3 FY2025 2025-09-30 | $27M | $15M | -$17M | -$14M | -$0.33 | -$9M† | $1M† |
| Q2 FY2025 2025-06-30 | $23M | $13M | -$20M | -$17M | -$0.39 | -$14M† | $2M† |
| Q1 FY2025 2025-03-31 | $18M | $9M | -$19M | -$29M | -$0.93 | -$20M | $333000 |
| Q4 FY2024 2024-12-31 | $20M† | $12M† | -$13M† | -$18M† | -$2.74† | -$14M† | $561000† |
| Q3 FY2024 2024-09-30 | $17M | $9M | -$11M | -$10M | -$1.46 | -$10M† | $2M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$44M
- Short-term investments$136M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BETA BIONICS INC looks technically
BETA BIONICS INC (BBNX) is trading 11.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 45.8% below its highest point of the past year. Trading volume is unusually light — only about 48% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 11.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.02 | $19.02 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.95 | $15.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 23.56. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal | 27 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 11.3% above | +11.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.7 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($16.32 to $19.44) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 45.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $32.71 | $32.71 |
|---|---|---|
| From the 52-week high | it is 45.8% below its 52-week high (its highest price of the past year) | -45.8% |
| Above the 52-week low | it is 101.6% above its 52-week low (its lowest price of the past year) | +101.6% |
| Below the 52-week high | it is 45.8% below its highest point of the past year | 45.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $32.71 (set on 2025-11-26) | $32.71 |
| Given back of the 52-week move | over the past year its closes ranged ($8.86 to $31.99), and it has recovered roughly a third of its fall from last year’s high — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.15 to $23.89. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.4% |
| From the all-time high | it is 45.8% below its all-time high | -45.8% |
| Nearest price level | it is trading 9.5% above a support level at $16.06 — a price it turned at twice since 2025-05-20, most recently on 2026-01-13. Since 2025-01-30 it has 5 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -9.5% |
| All-time low | its lowest closing price on record is $8.80 (set on 2026-04-10) | $8.80 |
| Above the all-time low | it is 101.6% above its all-time low | +101.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 36th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.14 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.41 and $21.95 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.41 – $18.68 – $21.95 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (11.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 48% of its 30-day average | 0.48× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.8% |
|---|---|---|
| Gap filled | a 3.2% gap down opened on 2026-09-16 has been "filled" 24 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 24 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +8.5% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.9 percentage points (the stock lost 19.0% while the market gained 1.0%) | -19.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.1 percentage points (the stock lost 0.4% while the market gained 3.6%) | -4.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.9 percentage points (the stock gained 37.4% while the market gained 8.5%) | +28.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 26.9 percentage points (the stock lost 12.4% while the market gained 14.6%) | -26.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.6% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.9% of the share price. | +0.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $15.60 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +13.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $18.34 — a volume-weighted average of daily closes over 59 sessions, not a true tick-by-tick VWAP. | -3.3% |
Rising wedge, bearish — broke down · entry $18.76 · 65 sessions in
Price levels it has turned at before
BBNX last closed at $17.74 on 2026-10-20. Since 2025-01-30 it has turned at 5 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.06 | Support | 9.5% below the last close | turned there twice · 2025-05-20 to 2026-01-13 |
| $15.60 | Support | 12.1% below the last close | turned there three times · 2025-05-08 to 2026-09-14 |
| $20.24 | Resistance | 14.1% above the last close | turned there twice · 2025-06-05 to 2026-09-01 |
| $13.70 | Support | 22.8% below the last close | turned there twice · 2025-03-10 to 2025-07-29 |
| $23.48 | Resistance | 32.4% above the last close | turned there twice · 2025-10-09 to 2026-09-22 |
| $24.34 | Resistance | 37.2% above the last close | turned there twice · 2025-02-07 to 2025-11-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $23.56.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke down to a new 20-day low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$24.24 range $16.00 – $30.40; median $25.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BBNX
- Consensus EPS estimate-$0.5133 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.00333 from -$0.51, on 2026-09-15, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on third-party manufacturers and single-source suppliers for critical product components.","Ability to maintain regulatory approval and comply with evolving US regulatory requirements.","Market acceptance and the ability to compete against established diabetes management companies."]
What changed in the latest 10-Q
AI-assisted comparison of BBNX's 10-Q filed 2026-07-29 against the prior one filed 2026-04-21.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-29) states that approximately 69% and 71% of the iLet's adoption during the six months ended June 30, 2026 and 2025, respectively, came from PWD previously utilizing MDI.
- Newer filing (2026-07-29) includes the sentence 'Unless the context requires otherwise, references in this Quarterly Report to the "Company,""we," "us" and "our" refer to Beta Bionics, Inc.' which is not present in the older filing.
- Removed:
- Older filing (2026-04-21) states that approximately 70% and 71% of the iLet's adoption during the three months ended March 31, 2026 and 2025, respectively, came from PWD previously utilizing MDI.
- Reworded:
- Older filing (2026-04-21) describes insulin requirements as 'everchanging'; newer filing (2026-07-29) uses 'ever-changing'.
- Older filing (2026-04-21) refers to 'general administrative functions'; newer filing (2026-07-29) refers to 'general and administrative functions'.
- Older filing (2026-04-21) describes 'clinical practices' in the PCP discussion; newer filing (2026-07-29) describes 'clinical practices' as well but the MDI adoption sentence was changed from three-month periods to six-month periods.
- Notes:
- The newer filing text appears to be truncated mid-sentence at the end of the provided excerpt, and the older filing text is also truncated, so comparison is limited to the portions provided.
Risk Factors
- Added:
- Newer filing (2026-07-29) states that there have been no material changes to risk factors "other than as described below", whereas older filing (2026-04-21) stated there were no material changes without qualification.
- Newer filing (2026-07-29) adds the heading "Risks Related to the Development, Regulatory Approval and Commercialization of our iLet Bionic Pancreas and Product Candidates".
- Newer filing (2026-07-29) adds a risk factor describing dependence on the iLet, including details about commercialized device status, bihormonal system development, glucagon NDA requirements, and 510(k) expectations for infusion pump and algorithm.
- Newer filing (2026-07-29) adds disclosure that the company is developing Mint, an insulin pump/patch pump, and has submitted a 510(k) application to the FDA.
- Newer filing (2026-07-29) adds disclosure that the company currently expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance.
- Newer filing (2026-07-29) adds a bulleted list of risks related to development, regulatory approval and commercialization, including preclinical studies, clinical trials, financing, regulatory activities, manufacturing, collaborations, sales, marketing, distribution, payer acceptance, competition, intellectual property, and organization building.
- Newer filing (2026-07-29) adds a paragraph discussing limitations on marketing authorization or clearance for other iLet configurations or indications and the potential inability to generate sufficient revenue.
- Newer filing (2026-07-29) adds a risk factor heading and paragraph text about dependence on iLet success and failure to advance iLet or Mint platforms.
- Newer filing (2026-07-29) adds a page number reference (41) within the risk factor text.
- Reworded:
- Older filing (2026-04-21) stated "There have been no material changes to the risk factors disclosed in the aforementioned Annual Report." Newer filing (2026-07-29) changed this to "Other than as described below, there have been no material changes to the risk factors disclosed in the aforementioned Annual Report."
- Notes:
- The newer filing section provided appears truncated at the end: the text cuts off mid-sentence ("including in a bihor"), so not all risk factor content may be captured.
- The older filing section includes non-Risk Factor content (Items 2-6, signatures), likely because the older filing's Risk Factors section was the introductory no-material-changes statement only; only the Risk Factors statement from the older filing was used for comparison.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 14 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 3 sells ($168351) — 2 selling insiders
- Last 90 days · read to 2026-10-160 buys · 14 sells ($3M) — 6 selling insiders
- Last 180 days · read to 2026-10-160 buys · 30 sells ($4M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BBNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BBNX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,405,975
- Reported value $69,041,628
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BBNX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BBNX had 6,046,389 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
BBNX had 13.4% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.25 days to cover at the same settlement.
- Reported short interest (shares) 6,046,389
- Short interest (% of shares outstanding) 13.4%
- Prior settlement (shares) 10,617,768
- Reported change -43.05%
- Days to cover (reported) 3.25
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BBNX vs…
BETA BIONICS INC is found in…
Frequently asked questions
What does BETA BIONICS INC (BBNX) do?
Beta Bionics is a medical technology company focused on the development and commercialization of automated insulin delivery systems for the management of diabetes. The company's primary technology is designed to simplify insulin delivery through automated control, with the goal of improving glycemic outcomes for individuals with diabetes.
What sector is BETA BIONICS INC (BBNX) in?
BETA BIONICS INC (BBNX) is classified in the Health Care sector. Its industry is medical devices / diabetes care. It trades on NASDAQ.
Who are BETA BIONICS INC's (BBNX) competitors?
Notable peers of BETA BIONICS INC (BBNX) include DexCom, Insulet, Medtronic, Tandem Diabetes Care and Abbott Laboratories. This peer set is informational only — not financial advice.
Is BETA BIONICS INC (BBNX) overbought or oversold right now?
BETA BIONICS INC (BBNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BBNX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.